1-5 of 5
Norman E. Sharpless
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings

Bryce A. Seifert, Julianne M. O'Daniel, Krunal Amin, Daniel S. Marchuk, Nirali M. Patel, Joel S. Parker, Alan P. Hoyle, Lisle E. Mose, Andrew Marron, Michele C. Hayward, Christopher Bizon, Kirk C. Wilhelmsen, James P. Evans, H. Shelton Earp, III, Norman E. Sharpless, D. Neil Hayes, Jonathan S. Berg
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16): 4087–4094.
https://doi.org/10.1158/1078-0432.CCR-16-0015
Published: 14 August 2016
View article titled, Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings
Open the PDF for Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings in another window
Journal Articles

IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

Craig C. Carson, Stergios J. Moschos, Sharon N. Edmiston, David B. Darr, Nana Nikolaishvili-Feinberg, Pamela A. Groben, Xin Zhou, Pei Fen Kuan, Shaily Pandey, Keefe T. Chan, Jamie L. Jordan, Honglin Hao, Jill S. Frank, Dennis A. Hopkinson, David C. Gibbs, Virginia D. Alldredge, Eloise Parrish, Sara C. Hanna, Paula Berkowitz, David S. Rubenstein, C. Ryan Miller, James E. Bear, David W. Ollila, Norman E. Sharpless, Kathleen Conway, Nancy E. Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (9): 2167–2176.
https://doi.org/10.1158/1078-0432.CCR-14-1826
Published: 30 April 2015
View article titled, IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Open the PDF for IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma in another window
Includes: Supplementary data
Journal Articles

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Zhao Chen, Esra Akbay, Oliver Mikse, Tanya Tupper, Katherine Cheng, Yuchuan Wang, Xiaohong Tan, Abigail Altabef, Sue-Ann Woo, Liang Chen, Jacob B. Reibel, Pasi A. Janne, Norman E. Sharpless, Jeffrey A. Engelman, Geoffrey I. Shapiro, Andrew L. Kung, Kwok-Kin Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1204–1211.
https://doi.org/10.1158/1078-0432.CCR-13-1733
Published: 02 March 2014
View article titled, Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <em>ALK</em>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Open the PDF for Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <em>ALK</em>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance in another window
Includes: Supplementary data
Journal Articles

Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

Jerry Usary, Wei Zhao, David Darr, Patrick J. Roberts, Mei Liu, Lorraine Balletta, Olga Karginova, Jamie Jordan, Austin Combest, Arlene Bridges, Aleix Prat, Maggie C. U. Cheang, Jason I. Herschkowitz, Jeffrey M. Rosen, William Zamboni, Norman E. Sharpless, Charles M. Perou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (17): 4889–4899.
https://doi.org/10.1158/1078-0432.CCR-13-0522
Published: 02 September 2013
View article titled, Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice
Open the PDF for Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice in another window
Includes: Supplementary data
Journal Articles

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

Patrick J. Roberts, Jerry E. Usary, David B. Darr, Patrick M. Dillon, Adam D. Pfefferle, Martin C. Whittle, James S. Duncan, Soren M. Johnson, Austin J. Combest, Jian Jin, William C. Zamboni, Gary L. Johnson, Charles M. Perou, Norman E. Sharpless
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5290–5303.
https://doi.org/10.1158/1078-0432.CCR-12-0563
Published: 30 September 2012
View article titled, Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
Open the PDF for Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models in another window
Includes: Supplementary data